Clinical trial
BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell…
NCT00411632 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00411632 |
|---|---|
| Title | BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) |
| Official title | A Phase II Study of Erlotinib (Tarceva) in Combination With Bexarotene (Targretin) in Chemorefractory Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | United States Department of Defense U.S. Fed |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | Bexarotene, Erlotinib |
| Enrollment | 37 |
| Start date | Nov 29, 2006 |
| Primary completion | Feb 23, 2018 |
| Completion | Feb 23, 2018 |
| First posted | Dec 14, 2006 |
| Last update posted | Jan 29, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: